Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Chuikyo OKs Requirements for Hospitals Offering Mixed Care in Economic Zones
The Central Social Insurance Medical Council (Chuikyo) on November 19 endorsed, after some fine-tuning, eligibility requirements for hospitals that can provide publicly uninsured healthcare services together with insured ones in a fast-track senshin-iryo scheme allowed in Tokyo and Kansai economic…
To read the full story
Related Article
- MHLW Picks 4 Hospitals Eligible for Special Mixed Care Scheme in Tokyo Economic Zone
February 20, 2015
- 5 Experts Likely to Review Regenerative Medicines for Expedited Senshin-Iryo Scheme
November 10, 2014
- Chuikyo OKs New Review Organs for Regenerative Medicines and Medical Devices under Senshin-Iryo System
October 24, 2014
- Mixed Care to Be Boosted in Tokyo, Kansai Special Economic Zones: Panel
March 31, 2014
REGULATORY
- Japan Targets Global-Level Growth for Domestic Patented Drug Market
June 25, 2026
- Paxlovid, Awiqli Braced for NHI Price Cuts after CEAs
June 25, 2026
- Drug Pricing to Be Applied to Oncolys Oncolytic Virus Therapy
June 25, 2026
- Japan Diet Begins Deliberations on Immunization Act Revision
June 25, 2026
- Expert Calls for AMR Ecosystem to Boost Japan Antibiotic Innovation
June 25, 2026
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Recent trends are creating a fascinating push-and-pull effect in the talent market. We’re seeing more positions opening up, but also a greater number of candidates available, particularly in the fields of rare diseases and oncology. This “more positions, more candidates”…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…